Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 3
2022 7
2023 17
2024 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Long COVID After Bamlanivimab Treatment.
Evering TH, Moser CB, Jilg N, Yeh E, Sanusi B, Wohl DA, Daar ES, Li JZ, Klekotka P, Javan AC, Eron JJ, Currier JS, Hughes MD, Smith DM, Chew KW; ACTIV-2/A5401 Study Team. Evering TH, et al. J Infect Dis. 2023 Aug 31;228(Suppl 2):S126-S135. doi: 10.1093/infdis/jiad286. J Infect Dis. 2023. PMID: 37650236 Free PMC article. Clinical Trial.
Variant-Specific Viral Kinetics in Acute COVID-19.
Ribeiro RM, Choudhary MC, Deo R, Giganti MJ, Moser C, Ritz J, Greninger AL, Regan J, Flynn JP, Wohl DA, Currier JS, Eron JJ, Hughes MD, Smith DM, Chew KW, Daar ES, Perelson AS, Li JZ; ACTIV-2/A5401 Study Team. Ribeiro RM, et al. J Infect Dis. 2023 Aug 31;228(Suppl 2):S136-S143. doi: 10.1093/infdis/jiad314. J Infect Dis. 2023. PMID: 37650233 Free PMC article. Clinical Trial.
Immune Status and SARS-CoV-2 Viral Dynamics.
Li Y, Moser C, Aga E, Currier JS, Wohl DA, Daar ES, Ritz J, Greninger AL, Sieg S, Parikh UM, Coombs RW, Hughes MD, Eron JJ, Smith DM, Chew KW, Li JZ; ACTIV-2/A5401 Study Team. Li Y, et al. J Infect Dis. 2023 Aug 31;228(Suppl 2):S111-S116. doi: 10.1093/infdis/jiad200. J Infect Dis. 2023. PMID: 37650232 Free PMC article. Clinical Trial.
Viral and Symptom Rebound in Untreated COVID-19 Infection.
Deo R, Choudhary MC, Moser C, Ritz J, Daar ES, Wohl DA, Greninger AL, Eron JJ, Currier JS, Hughes MD, Smith DM, Chew KW, Li JZ; ACTIV-2/A5401 Study Team. Deo R, et al. medRxiv [Preprint]. 2022 Aug 2:2022.08.01.22278278. doi: 10.1101/2022.08.01.22278278. medRxiv. 2022. PMID: 35982660 Free PMC article. Preprint.
Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial.
Jagannathan P, Chew KW, Giganti MJ, Hughes MD, Moser C, Main MJ, Monk PD, Javan AC, Li JZ, Fletcher CV, McCarthy C, Wohl DA, Daar ES, Eron JJ, Currier JS, Singh U, Smith DM, Fischer W; ACTIV-2/A5401 Study Team. Jagannathan P, et al. EClinicalMedicine. 2023 Oct 6;65:102250. doi: 10.1016/j.eclinm.2023.102250. eCollection 2023 Nov. EClinicalMedicine. 2023. PMID: 37855026 Free PMC article.
Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody Therapy.
Choudhary MC, Chew KW, Deo R, Flynn JP, Regan J, Crain CR, Moser C, Hughes M, Ritz J, Ribeiro RM, Ke R, Dragavon JA, Javan AC, Nirula A, Klekotka P, Greninger AL, Fletcher CV, Daar ES, Wohl DA, Eron JJ, Currier JS, Parikh UM, Sieg SF, Perelson AS, Coombs RW, Smith DM, Li JZ; ACTIV-2/A5401 Study Team. Choudhary MC, et al. medRxiv [Preprint]. 2021 Sep 15:2021.09.03.21263105. doi: 10.1101/2021.09.03.21263105. medRxiv. 2021. PMID: 34545376 Free PMC article. Preprint.
Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19.
Chew KW, Moser C, Daar ES, Wohl DA, Li JZ, Coombs RW, Ritz J, Giganti M, Javan AC, Li Y, Choudhary MC, Deo R, Malvestutto C, Klekotka P, Price K, Nirula A, Fischer W, Bala V, Ribeiro RM, Perelson AS, Fletcher CV, Eron JJ, Currier JS; ACTIV-2/A5401 Study Team; Hughes MD, Smith DM. Chew KW, et al. Nat Commun. 2022 Aug 22;13(1):4931. doi: 10.1038/s41467-022-32551-2. Nat Commun. 2022. PMID: 35995785 Free PMC article. Clinical Trial.
Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial.
Choudhary MC, Chew KW, Deo R, Flynn JP, Regan J, Crain CR, Moser C, Hughes MD, Ritz J, Ribeiro RM, Ke R, Dragavon JA, Javan AC, Nirula A, Klekotka P, Greninger AL, Fletcher CV, Daar ES, Wohl DA, Eron JJ, Currier JS, Parikh UM, Sieg SF, Perelson AS, Coombs RW, Smith DM, Li JZ; ACTIV-2/A5401 Study Team. Choudhary MC, et al. Nat Microbiol. 2022 Nov;7(11):1906-1917. doi: 10.1038/s41564-022-01254-1. Epub 2022 Oct 26. Nat Microbiol. 2022. PMID: 36289399 Free PMC article. Clinical Trial.
Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection.
Deo R, Choudhary MC, Moser C, Ritz J, Daar ES, Wohl DA, Greninger AL, Eron JJ, Currier JS, Hughes MD, Smith DM, Chew KW, Li JZ; ACTIV-2/A5401 Study Team. Deo R, et al. Ann Intern Med. 2023 Mar;176(3):348-354. doi: 10.7326/M22-2381. Epub 2023 Feb 21. Ann Intern Med. 2023. PMID: 36802755 Free PMC article. Clinical Trial.
35 results